☆ 4.7 Review

Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer

ANNALS OF SURGICAL ONCOLOGY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

Cytoreductive Surgery With or Without HIPEC After Neoadjuvant Chemotherapy in Ovarian Cancer: A Phase 3 Clinical Trial

Cascales Campos Pedro Antonio et al.

Summary: In this study, for patients with advanced ovarian cancer treated with neoadjuvant systemic chemotherapy, cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) were associated with improved disease-free survival and overall survival. However, there were no differences in postoperative morbidity, mortality, or quality of life evaluation between the CRS with or without HIPEC groups.

ANNALS OF SURGICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Disparity of ovarian cancer survival between urban and rural settings

Keely Krolikowski Ulmer et al.

Summary: This study found that patients with ovarian cancer living in rural areas with smaller populations and greater distance to tertiary care centers have poorer survival rates in the United States.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2022)

添加到收藏夹

Article Oncology

Modifiable risk factors associated with long-term survival in women with serous ovarian cancer: a National Cancer Database study

Anja Sophia Frost et al.

Summary: This study aims to identify patient, clinical and hospital factors associated with long-term survival in women with serous ovarian cancer. The study found that factors such as age, comorbidities, stage, grade, and insurance type are associated with long-term survival, providing an opportunity for improving care and impacting patient outcomes.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2022)

添加到收藏夹

Article Surgery

Survival After Hyperthermic Intraperitoneal Chemotherapy and Primary or Interval Cytoreductive Surgery in Ovarian Cancer A Randomized Clinical Trial

Myong Cheol Lim et al.

Summary: The study aimed to evaluate the clinical benefit of HIPEC in patients with ovarian cancer. The results showed that adding HIPEC to cytoreductive surgery did not improve survival rates for patients with advanced ovarian cancer. However, in the subgroup of interval cytoreductive surgery, the addition of HIPEC improved progression-free and overall survival.

JAMA SURGERY (2022)

添加到收藏夹

Article Obstetrics & Gynecology

Standardizing HIPEC and perioperative care for patients with ovarian cancer in the Netherlands using a Delphi-based consensus

Ruby M. van Stein et al.

Summary: This study aimed to standardize perioperative care for patients treated with CRS and HIPEC for ovarian cancer using a Delphi-based consensus approach. Dutch experts reached consensus on the majority of items, which can help align treatment protocols and minimize practice variation. However, consensus was not reached on some topics.

GYNECOLOGIC ONCOLOGY REPORTS (2022)

添加到收藏夹

Article Oncology

Complications and Mortality Rate of Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy: Italian Peritoneal Surface Malignancies Oncoteam Results Analysis

Fabio Carboni et al.

Summary: Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy is a valuable treatment option for selected patients with peritoneal surface malignancies, providing low rates of postoperative morbidity and mortality. However, this treatment is still only performed in specialized centers.

CANCERS (2022)

添加到收藏夹

Article Obstetrics & Gynecology

A randomized phase 3 trial of intraperitoneal versus intravenous carboplatin with dose-dense weekly paclitaxel in patients with ovarian, fallopian tube, or primary peritoneal carcinoma (a GOTIC-001/JGOG-3019/GCIG, iPocc Trial) (LBA 3)

Keiichi Fujiwara et al.

GYNECOLOGIC ONCOLOGY (2022)

添加到收藏夹

Article Obstetrics & Gynecology

Enrollment of Individuals From Racial and Ethnic Minority Groups in Gynecologic Cancer Precision Oncology Trials

Larissa H. Mattei et al.

Summary: This study found that precision oncology clinical trials for gynecologic cancers do not adequately reflect the racial and ethnic diversity of patients. Non-Hispanic Black women, Asian women, and Hispanic women are underrepresented in these trials. This lack of equitable enrollment may perpetuate disparities in gynecologic cancer outcomes, especially for uterine and cervical cancers which have higher morbidity and mortality rates in minority groups.

OBSTETRICS AND GYNECOLOGY (2022)

添加到收藏夹

Article Oncology

Patterns of recurrence in women with advanced and recurrent epithelial ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

Laura M. Chambers et al.

Summary: This study investigated recurrence patterns and outcomes in women with advanced or recurrent EOC after CRS+HIPEC treatment. The study found that half of the patients experienced their first recurrence outside of the peritoneal cavity. Recurrences in pelvic and upper abdominal sites were associated with reduced PFS and OS compared to recurrences in extra-peritoneal sites.

GYNECOLOGIC ONCOLOGY (2021)

添加到收藏夹

Editorial Material Oncology

State of the Science: The role of HIPEC in the treatment of ovarian cancer

Thanh H. Dellinger et al.

GYNECOLOGIC ONCOLOGY (2021)

添加到收藏夹

Article Oncology

HIPEC Methodology and Regimens: The Need for an Expert Consensus

Aditi Bhatt et al.

Summary: Standardization of HIPEC methodology and regimens is important for increasing the collective experience of peritoneal oncologists. However, current studies show limited preclinical and clinical data, and suggest the need for more translational research and phase studies while waiting for better evidence.

ANNALS OF SURGICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Disparities in ovarian cancer treatment and overall survival according to race: An update

Deanna L. Huffman et al.

Summary: This study retrospectively reviewed National Cancer Database records of White and Black women diagnosed with epithelial ovarian cancer from 2012 to 2016, finding significant differences in disease characteristics and survival rates between Black and White patients.

GYNECOLOGIC ONCOLOGY (2021)

添加到收藏夹

Article Oncology

What Drives High Costs of Cytoreductive Surgery and HIPEC: Patient, Provider or Tumor?

Patrick B. Schwartz et al.

ANNALS OF SURGICAL ONCOLOGY (2020)

添加到收藏夹

Review Oncology

Oncologic outcomes and morbidity following heated intraperitoneal chemotherapy at cytoreductive surgery for primary epithelial ovarian cancer: A systematic review and meta-analysis

Genevieve Bouchard-Fortier et al.

GYNECOLOGIC ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Guidelines for Perioperative Care in Cytoreductive Surgery (CRS) with or without hyperthermic IntraPEritoneal chemotherapy (HIPEC): Enhanced Recovery After Surgery (ERAS®) Society Recommendations - Part II: Postoperative management and special considerations

Martin Huebner et al.

EJSO (2020)

添加到收藏夹

Article Oncology

Guidelines for Perioperative Care in Cytoreductive Surgery (CRS) with or without hyperthermic IntraPEritoneal chemotherapy (HIPEC): Enhanced recovery after surgery (ERAS®) Society Recommendations - Part I: Preoperative and intraoperative management

Martin Hubner et al.

EJSO (2020)

添加到收藏夹

Article Oncology

Current status of hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer in the United States

Lindsey M. Charo et al.

GYNECOLOGIC ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Racial disparities in treatment and survival from ovarian cancer

Janet S. Hildebrand et al.

CANCER EPIDEMIOLOGY (2019)

添加到收藏夹

Article Oncology

Cost-effectiveness of hyperthermic intraperitoneal chemotherapy HIPEC) at interval debulking of epithelial ovarian cancer following neoadjuvant chemotherapy

Stephanie L. Lim et al.

GYNECOLOGIC ONCOLOGY (2019)

添加到收藏夹

Article Oncology

ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease

N. Colombo et al.

ANNALS OF ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Cost Effectiveness of Interval Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy in Stage III Ovarian Cancer on the Basis of a Randomized Phase III Trial

Simone N. Koole et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

添加到收藏夹

Editorial Material Oncology

Role of Intraperitoneal Therapy in the Initial Management of Ovarian Cancer

Deborah K. Armstrong et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

添加到收藏夹

Article Medicine, General & Internal

Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer

W. J. van Driel et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Editorial Material Oncology

Hyperthermic intraperitoneal chemotherapy (HIPEC) is cost-effective in the management of primary ovarian cancer

Kian Behbakht et al.

GYNECOLOGIC ONCOLOGY (2018)

添加到收藏夹

Article Oncology

OV21/PETROC: a randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer

D. M. Provencher et al.

ANNALS OF ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Current status and future prospects of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) clinical trials in ovarian cancer

Renee A. Cowan et al.

INTERNATIONAL JOURNAL OF HYPERTHERMIA (2017)

添加到收藏夹

Article Oncology

Routine Admission to Intensive Care Unit After Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy: Not Always a Requirement

Harveshp D. Mogal et al.

ANNALS OF SURGICAL ONCOLOGY (2016)

添加到收藏夹

Article Oncology

The generalizability of NCI-sponsored clinical trials accrual among women with gynecologic malignancies

Grace Mishkin et al.

GYNECOLOGIC ONCOLOGY (2016)

添加到收藏夹

Article Biochemistry & Molecular Biology

Hyperthermia: an effective strategy to induce apoptosis in cancer cells

Kanwal Ahmed et al.

APOPTOSIS (2015)

添加到收藏夹

Article Oncology

Effects of hyperthermia on DNA repair pathways: one treatment to inhibit them all

Arlene L. Oei et al.

RADIATION ONCOLOGY (2015)

添加到收藏夹

Article Oncology

Cytoreductive Surgery and HIPEC in Recurrent Epithelial Ovarian Cancer: A Prospective Randomized Phase III Study

J. Spiliotis et al.

ANNALS OF SURGICAL ONCOLOGY (2015)

添加到收藏夹

Article Oncology

Intraperitoneal chemotherapy among women in the Medicare population with epithelial ovarian cancer

Kathleen M. Fairfield et al.

GYNECOLOGIC ONCOLOGY (2014)

添加到收藏夹

Article Multidisciplinary Sciences

Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition

Przemek M. Krawczyk et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)

添加到收藏夹

Review Medicine, General & Internal

Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer

Kenneth Jaaback et al.

COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2011)

添加到收藏夹

Article Immunology

Heat Shock Protein 70, Released from Heat-Stressed Tumor Cells, Initiates Antitumor Immunity by Inducing Tumor Cell Chemokine Production and Activating Dendritic Cells via TLR4 Pathway

Taoyong Chen et al.

JOURNAL OF IMMUNOLOGY (2009)

添加到收藏夹

Article Medicine, General & Internal

Intraperitoneal cisplatin and paclitaxel in ovarian cancer

DK Armstrong et al.

NEW ENGLAND JOURNAL OF MEDICINE (2006)

添加到收藏夹

Article Oncology

Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intrapentoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: A Gynecologic Oncology Group study

JL Walker et al.

GYNECOLOGIC ONCOLOGY (2006)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.